Lincoln National Corp Iveric Bio, Inc. Transaction History

Lincoln National Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 04, 2023	SELL	$26.24 - $39.63 $239,728 - $362,059	-9,136 Reduced 16.32%	46,854 $1.84 Million
Q1 2023 May 01, 2023	BUY	$18.67 - $24.56 $96,225 - $126,582	5,154 Added 10.14%	55,990 $1.36 Million
Q4 2022 Feb 07, 2023	SELL	$17.24 - $23.95 $310,320 - $431,100	-18,000 Reduced 26.15%	50,836 $1.09 Million
Q3 2022 Nov 03, 2022	BUY	$9.4 - $18.59 $28 - $55	3 Added 0.0%	68,836 $1.24 Million
Q4 2021 Jan 26, 2022	BUY	$13.83 - $18.78 $46,095 - $62,593	3,333 Added 5.09%	68,833 $1.15 Million

Q3 2021 Nov 05, 2021	BUY	$7.07 - $17.5 $258,337 - $639,450	36,540 Added 126.17%	65,500 $1.06 Million
Q2 2021 Aug 13, 2021	BUY	$5.69 - $7.17 $164,782 - $207,643	28,960 New	28,960 $183,000

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Lincoln National Corp, based on Form 13F filings with the SEC.

Stay updated on Lincoln National Corp with notifications on news.